SillaJen, Inc. (KOSDAQ:215600)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,740.00
-50.00 (-1.32%)
At close: Feb 6, 2026
45.81%
Market Cap516.61B +34.1%
Revenue (ttm)7.84B +537.6%
Net Income-23.24B
EPS-168.70
Shares Out138.13M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,237,193
Average Volume4,182,791
Open3,700.00
Previous Close3,790.00
Day's Range3,600.00 - 3,855.00
52-Week Range1,873.00 - 5,400.00
Beta0.27
RSI51.52
Earnings DateMar 20, 2026

About SillaJen

SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-600 Series and JX-970 to treat solid tumors and is in preclinical trial. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 57
Stock Exchange KOSDAQ
Ticker Symbol 215600
Full Company Profile

Financial Performance

In 2024, SillaJen's revenue was 3.93 billion, a decrease of -0.33% compared to the previous year's 3.94 billion. Losses were -26.53 billion, 30.2% more than in 2023.

Financial Statements